Effects of cyclosporin A or betamethasone on experimental murine toxocariasis;Efeitos da ciclosporina A e betametasona na toxocaríase murina experimental

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 37, Issue 1, 2004, Pages 22-24

  Zevallos Lescano, Susana A ^a   Chieffi, Pedro Paulo ^a,b   Ikai, Denise Katia ^a   Ribeiro, Manoel Carlos S A ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

Author keywords

Betamethasone; Cyclosporin A; Experimental toxocariasis; Mice; Toxocara canis

Indexed keywords

BETAMETHASONE; CYCLOSPORIN A; IMMUNOGLOBULIN G ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL INFECTION; LARVA; LIVER; LUNG; MOUSE; MUSCLE; NONHUMAN; TOXOCARA CANIS; TOXOCARIASIS;

ANIMALIA; CANIS; MURINAE; TOXOCARA; TOXOCARA CANIS;

EID: 1442350005     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0037-86822004000100006     Document Type: Article

References (19)

1. Armson A, Cunningham GA, Grubb WB, Mendis AH. Murine strongyloidiasis: the effects of cyclosporin A and thiabendazole administered singly and in combination. International Journal for Parasitology 25: 533-535, 1995.
2. Barriga OO. A critical look at the importance, prevalence and control of toxocariasis and the possibilities of immunological control. Veterinary Parasitology 29: 195-234, 1988.
3. Bell A, Roberts HC, Chappell LH. The antiparasite effects of cyclosporin A: possible drug targets and clinical applications. General Pharmacology 27: 963-971, 1996.
4. Chappell LH, Wastling JM. Cyclosporin A: antiparasite drug, modulator of the host-parasite relationship and immunosuppressant. Parasitology 105: 525-540, 1992.
5. Chieffi PP, Peres BA, Mello EO, Kanamura H, Brandão M. Persistence of specific antibody response in different experimental infection of mice with Toxocara canis. Revista do Instituto de Medicina Tropical de São Paulo 37: 187-190, 1995.
6. Chieffi PP, Ueda M, Camargo ED, Souza AM, Guedes MLS, Gerbi LJ, Spir M, Moreira AS. Visceral larva migrans: a seroepidemiological survey in five municipalities of São Paulo State, Brazil. Revista do Instituto de Medicina Tropical de São Paulo 32:204-210, 1990.
7. El-Ganayni GA, Handousa AE. The effect of cyclosporin A (CSA) on murine visceral toxocariasis canis. Journal of the Egyptian Society of Parasitology 22: 487-494, 1992.
8. Gargione C, Vellosa SAG, Shimizu SH, Okumura M, Chiodelles SG. Immunosuppression and parasitic diseases: experimental Schistosoma mansoni. Revista do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, 53: 122-128, 1998.
9. Glickman LT, Schantz PM, Dombroske R, Cypess R. Evaluation of serodiagnostic tests for visceral larva migrans. American Journal of Tropical Medicine and Hygiene 27: 492-498, 1978.
10. Hurd H, Mackenzie KS, Chappell I.H. Anthelmintic effects of cyclosporin A on protoscoleces and secondary hidatid cysts of Echinicoccus granulosus in the mouse. International Journal for Parasitology 23: 315-320, 1993.
11. McLauchlan PE, Roberts HC, Chappell LH. Mode of action of cyclosporin A against Hymenolepis microstoma (Cestoda): relationship between cyclophilin binding and drug-induced damage. Parasitology 121: 661-670, 2000.
12. Overgaauw PAM. Aspects of Toxocara epidemiology: toxocarosis in dogs and cats. Critical Review in Microbiology 23:233-251, 1997.
13. Palau LA, Pankey GA. Strongyloides hyperinfection in a renal transplant recipient receiving cyclosporine: possible Strongyloides stercoralis transmission by kidney transplant. American Journal of Tropical Medicine and Hygiene 57:413-415, 1997.
14. Portus M, Riera C, Prats G. A serological survey of toxocariasis in patients and healthy donors in Barcelona (Spain). European Journal of Epidemiology 5:224-227, 1989.
15. Ryffel B. Cyclosporin binding proteins. Identificatioon, distribution, function and relation to FK binding proteins. Biochemical Pharmacology 46: 1-12, 1993.
16. Schantz PM. Toxocara larva migrans now. American Journal of Tropical Medicine and Hygiene 41:21-34, 1989.
17. Taylor MRH, Keane CT, O'Connor P, Girdwood RWA, Smith H. Clinical features of covert toxocariasis. Scandinavian Journal of Infectious Diseases 19: 693-696, 1987.
18. Thompson DE, Bundy DAP, Cooper ES, Schantz PM. Epidemiological characteristics of Toxocara canis zoonotic infection of children in a Caribbean community. Bulletin of the World Health Organization 64:283-290, 1986.
19. Xi WG, Jin LZ. A novel method for the recovery of Toxocara canis in mice. Journal of Helminthology 72: 183-184, 1998.